Active	Status	Sponsor type	Region	Phase	Filter
3 Active 6 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Raderer, Markus
NCT03474744 / 2017-003150-16: Copanlisib and Rituximab in Marginal Zone Lymphoma Patients	Active, not recruiting	2	36	Europe	Copanlisib, Aliqopa, Rituximab, Truxima	Christian Buske, University of Ulm, Optimapharm, X-act Cologne Clinical Research GmbH, Zentrum für Klinische Studien Ulm, Celltrion Healthcare Co., LTD, Bayer	Marginal Zone Lymphoma	06/24	12/29
NCT04646395: Study of Acalabrutinib and Tafasitamab in MZL Patients	Active, not recruiting	2	26	Europe	Tafasitamab, MOR00208, Acalabrutinib, Calquence	International Extranodal Lymphoma Study Group (IELSG)	Marginal Zone Lymphoma	09/27	03/28
NCT04268277: Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY	Recruiting	N/A	56	Europe	Rituximab, Truxima, Pembrolizumab, Keytruda	University of Ulm, X-act Cologne Clinical Research GmbH, Zentrum für Klinische Studien Ulm, Merck Sharp & Dohme LLC, Celltrion Healthcare Co., LTD	Marginal Zone Lymphoma	04/29	04/29